Benitec Biopharma Inc.2025财年第一财季实现净利润-9.35百万美元，同比减少118.46%

市场透视2025-05-23

5月23日，Benitec Biopharma Inc.（BNTC.US）公布财报，公告显示公司2025财年第一财季净利润为-9.35百万美元，同比减少118.46%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Benitec Biopharma Inc.（BNTC.US）总负债7.64百万美元，其中短期债务346000.00美元，资产负债比为0.14，流动比率为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537923176?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537923176","market":"us","top_or_hot":-1,"title":"Benitec Biopharma Inc.2025财年第一财季实现净利润-9.35百万美元，同比减少118.46%","media":"市场透视","content":"<div>\n<p>5月23日，Benitec Biopharma Inc.（BNTC.US）公布财报，公告显示公司2025财年第一财季净利润为-9.35百万美元，同比减少118.46%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Benitec Biopharma Inc.（BNTC.US）总负债7.64百万美元，其中短期债务346000.00美元，资产负债比为0.14，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000029a6e913e6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Benitec Biopharma Inc.2025财年第一财季实现净利润-9.35百万美元，同比减少118.46%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBenitec Biopharma Inc.2025财年第一财季实现净利润-9.35百万美元，同比减少118.46%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000029a6e913e6&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月23日，Benitec Biopharma Inc.（BNTC.US）公布财报，公告显示公司2025财年第一财季净利润为-9.35百万美元，同比减少118.46%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Benitec Biopharma Inc.（BNTC.US）总负债7.64百万美元，其中短期债务346000.00美元，资产负债比为0.14，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000029a6e913e6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTC","symbol_name":"Benitec Biopharma Limited","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000029a6e913e6&s=b","article_id":"2537923176","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000029a6e913e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537923176","pubTimestamp":1747929620,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月23日，Benitec Biopharma Inc.公布财报，公告显示公司2025财年第一财季净利润为-9.35百万美元，同比减少118.46%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Benitec Biopharma Inc.总负债7.64百万美元，其中短期债务346000.00美元，资产负债比为0.14，流动比率为0.15。机构评级：截至2025年5月23日，当前有7家机构对Benitec Biopharma Inc.目标价做出预测，其中目标均价为25.71美元，其中最低目标价为17.00美元，最高目标价为35.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"BNTC":"Benitec Biopharma Limited"},"translate_title":"Benitec Biopharma Inc. achieved net profit of-9.35 million US dollars in the first fiscal quarter of fiscal year 2025, a year-on-year decrease of 118.46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTC":0.9},"content_text":"5月23日，Benitec Biopharma Inc.（BNTC.US）公布财报，公告显示公司2025财年第一财季净利润为-9.35百万美元，同比减少118.46%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Benitec Biopharma Inc.（BNTC.US）总负债7.64百万美元，其中短期债务346000.00美元，资产负债比为0.14，流动比率为0.15。机构评级：截至2025年5月23日，当前有7家机构对Benitec Biopharma Inc.目标价做出预测，其中目标均价为25.71美元，其中最低目标价为17.00美元，最高目标价为35.00美元。公司简介：Benitec Biopharma Inc 是一家临床阶段的生物技术公司，专注于新型基因药物的开发。它的技术有可能为多种疾病提供一次性治愈方法，这些疾病需要严格的持续治疗方案或没有有效的治疗方法或只有姑息治疗选择。该公司正在开发一种基于沉默和替代的疗法 (BB-301)，用于治疗眼咽肌营养不良症 (OPMD)，这是一种慢性、危及生命的遗传疾病。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537923176","isCrawlerRequest":true}